CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 591 enrolled
Drug / intervention
Rheos® Baroreflex Hypertension Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00442286
NCT00442286N/ACompleted

Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System

CVRx, Inc.·interventional·Posted Mar 1, 2007·Updated Mar 20, 2017

In Brief

A clinical study evaluating Rheos® Baroreflex Hypertension System for Hypertension. Completed, enrolled 591 participants across 44 sites in 3 countries.

Detailed Summary

The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with hypertension that are resistant to treatment with at least three anti-hypertension agents, one of which is a diuretic.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesGermany, Netherlands, United States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 1, 2007
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 19.3 years ago

Interventions

Rheos® Baroreflex Hypertension Systemdevice

Electrical activation of the Carotid Baroreflex